Clinical trial
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
NCT00137826 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00137826 |
|---|---|
| Title | Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma |
| Official title | Phase II Study of Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Malignant Mesothelioma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Massachusetts General Hospital University of Chicago |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mesothelioma |
| Intervention type | Drug |
| Interventions | Erlotinib, Bevacizumab |
| Enrollment | 37 |
| Start date | Feb 1, 2004 |
| Primary completion | Mar 1, 2007 |
| Completion | Jul 1, 2009 |
| First posted | Aug 30, 2005 |
| Last update posted | Dec 26, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: